Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma (Q40333268)
Jump to navigation
Jump to search
scientific article published on January 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma |
scientific article published on January 2006 |
Statements
1 reference
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma (English)
1 reference
John F DiJoseph
1 reference
Maureen M Dougher
1 reference
Lyka B Kalyandrug
1 reference
Douglas C Armellino
1 reference
Erwin R Boghaert
1 reference
Philip R Hamann
1 reference
Justin K Moran
1 reference
Nitin K Damle
1 reference
1 January 2006
1 reference
1 reference
Identifiers
1 reference